title: [Selection of antibacterial therapy for treatment of infections in elderly patients].
abstract: Examination of 60 elderly outpatients with lower respiratory tract infections (LRTI) revealed that 73 per cent of the patients isolated the pathogen associations and only 27 per cent isolated the monocultures. Grampositive cocci including Streptococcus pneumoniae were isolated from 70 per cent of the patients, Haemophilus influenzae and H.parainfluenzae were isolated from 20 per cent of the patients and Acinetobacter spp., Citrobacter spp., Enterobacter spp., Proteus spp. and Pseudomonas aeruginsa were isolated from 10 per cent of the patients. The patients were treated with ciprofloxacin, cefaclor or amoxycillin/clavulanic acid. Ciprofloxacin proved to be the most efficient agent. The regimens of the ofloxacin use in a dose of 400 mg orally once a day or in a dose of 200 mg intravenously twice a day for 2-4 days followed by the oral use for 6-8 days in the treatment of 24 patients with LRTI hospitalized into a therapeutic unit were compared. it was shown (pharmacokinetically as well) that the regiment with the drug use in the single dose was more efficient. Lomefloxacin was suggested to be the most advantageous drug in the treatment of elderly patients with LRTI because of its easy use, practically no dependence of the pharmacokinetics on the patient age and almost no nephrotoxic action.
authors.affiliation: Russia State Medical University, Moscow.
authors.forename: Iu B
authors.initials: IuB
authors.lastname: Belousov
authors.forename: V P
authors.initials: VP
authors.lastname: Komarova
authors.forename: O V
authors.initials: OV
authors.lastname: Efremenkova
mesh_terms: D000368:Aged; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002433:Cefaclor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D015363:Quinolones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D015363:Quinolones; D002939:Ciprofloxacin; D002433:Cefaclor; D019980:Amoxicillin-Potassium Clavulanate Combination; C053091:lomefloxacin
vernacular_title: Vybor antibakterial'noĭ terapii pri lechenii infektsiĭ u lits pozhilogo vozrasta.